Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 Docking Structural Analysis with Phytochemical Extracts of Rosemary: A Possible Cytotoxicity on Head and Neck Squamous Cell Carcinoma Cell Line (HEp-2).
|
31244433 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, targeting COX-2 could be a promising strategy for the treatment of HNSCC.
|
27696591 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For unadjusted data, an association with increased risk was observed in three genetic models in COX-2 rs689466 polymorphism; however, COX-2 rs5275 and rs20417 polymorphisms were not related to HNSCC risk in this study.
|
27412115 |
2016 |
Squamous cell carcinoma of the head and neck
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CONCLUSIONS This meta-analysis indicated that COX-2 rs689466 polymorphism might be associated with increased susceptibility to HNSCC.
|
26568042 |
2015 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated whether the endoplasmic reticulum (ER) stress response could be a cyclooxygenase-2 (COX2)-independent mechanism of growth inhibition by celecoxib in a head and neck squamous cell carcinoma (HNSCC) cell line.
|
24692703 |
2014 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We used quantitative real-time PCR to examine the effects of three selective Cox-2 inhibitors, i.e., celecoxib, NS-398, and SC-791 on the gene expressions of E-cadherin (CDH-1) and its transcriptional repressors (SIP1, Snail, Twist) in the human HNSCC cell lines HSC-2 and HSC-4.
|
24887090 |
2014 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that not only COX-2 expression, but also the expression of 5-LO and CYP2J2 is up-regulated in head and neck squamous cell carcinoma (HNSCC) cell lines.
|
21656078 |
2012 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our study suggests that, as COX-1 and COX-2 express and affect VEGF synthesis in HNSCC cells, we should check COX-1 expression in investigations on cancer treatment by inhibiting COX-2-induced prostaglandins.
|
21301321 |
2011 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Importantly, treatment of HNSCC cells with GS abrogated both ST- and nicotine-induced nuclear activation of NF-κB and pSTAT3 proteins and their downstream targets COX-2 and vascular endothelial growth factor.
|
21177768 |
2011 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on these results, the COX-2 haplotype ht3 can be used as a molecular biomarker to predict low risk groups of SCCHN in a Korean sample.
|
20592893 |
2010 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results presented here show that HNSCC tumoral lesions and their derived cell lines constitutively express COX-2 and the EP1, EP2 and EP3 receptors for PGE2.
|
20951077 |
2010 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was overexpression of COX-2 and its downstream enzyme mPGES-1, and their localization in tumor cells was similar, suggesting that these enzymes play both an important role in the development and proliferation of HNSCC.
|
20034753 |
2010 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
The majority of the anticancer effects of COX-2-inhibitors in HNSCC cells seem to result from COX-2-independent action, suggesting that COX-1 and COX-2 may contribute to VEGF synthesis in cancer cells through a prostaglandin-dependent mechanism.
|
20222044 |
2010 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we investigated whether the regulation of mitogen-activated protein kinases activity might be one of the main mechanisms related to a conspicuous COX-2-independent tumor-killing effect of celecoxib in HNSCC cell lines.
|
20717005 |
2010 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, Sal-B shows promise as a COX-2 targeted anticancer agent for HNSCC prevention and treatment.
|
19123475 |
2009 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
As Cox-2 is known to inhibit radiotherapy responses in SCCHN patients, data indicate an additional mechanism through which DeltaNp63 acts to promote cell survival and influence therapeutic response of SCCHN.
|
19391123 |
2009 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
An inverse relationship between COX-2 and E-cadherin was shown in situ by double immunohistochemical staining of human HNSCC tissue sections.
|
19789323 |
2009 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bradykinin induced a concentration- and time-dependent induction of COX-2 protein in HNSCC, which was preceded by phosphorylation of EGFR and MAPK.
|
19074839 |
2008 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
|
17875728 |
2007 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
We did quantitative PCR analysis of cytochrome c oxidase (Cox) I and Cox II genes to measure changes in mtDNA content in pretreatment and posttreatment salivary rinses obtained from 76 patients undergoing surgical resection for primary head and neck squamous cell carcinoma.
|
16533782 |
2006 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumours and clinically normal non-neoplastic tissue from SCCHN patients showed increased expression of COX-2 and PP2A.
|
16273222 |
2005 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous study revealed that simultaneously targeting epidermal growth factor receptor (EGFR) tyrosine kinase and cyclooxygenase-2 (COX-2) additively or synergistically inhibited growth of squamous cell carcinoma of the head and neck (SCCHN) in vitro.
|
16144930 |
2005 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
BEFREE |
We did quantitative PCR of cytochrome c oxidase I (Cox I) and cytochrome c oxidase II (Cox II) genes on oral rinse samples obtained from 94 patients with primary head and neck squamous cell carcinoma (HNSC) and a control group of 656 subjects.
|
15814624 |
2005 |
Squamous cell carcinoma of the head and neck
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of p53 markedly downregulated the transcription of COX-2, but the overexpression of p27 did not affect COX-2 levels in HNSCC cell lines.
|
15287038 |
2004 |
Squamous cell carcinoma of the head and neck
|
0.400 |
Biomarker
|
disease |
CTD_human |
Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for COX-2 induction by areca quid ingredients in oral keratinocytes.
|
12969226 |
2003 |